The observation that a subset of breast cancers express the estrogen receptor (ER) led to the development of aromatase inhibitors, selective estrogen receptor degraders (SERDs) and selective estrogen receptor modulators (SERMs), which now make up a core component of standard clinical care for patients with ER positive disease [9–11]. This evidence concerns the gene ESR1 and breast carcinoma.